페이지 정보Date21-03-25 10:51 Number of views186
PharmaResearch Acquires ‘Method of Use Patent’ on Hyaluronic Acid Degradation Inhibitor.
‘MESNA’ for prevention of hemorrhagic cystitis, prolongs hyaluronic acid effect… expecting the collaboration of related products
PharmaResearch Products Co., Ltd. (CEO Shin-Kyu Kim, Ki-Seock Kang) announced on the 24th that it has acquired a ‘New Use Invention’ for ‘MESNA’ as an inhibitor of hyaluronic acid degradation in China.
This patent contains features that MESNA, known as a compound for preventing hemorrhagic cystitis caused by a specific anti-cancer agent, can be used to prevent the reduction of hyaluronic acid in the skin or skin tissue.
PharmaResearch will be guaranteed the exclusive right to manufacture biomaterial graft and prosthesis materials using MESNA as a degradation inhibitor of hyaluronic acid in China by February 2035.
An official at PharmaResearch said, “Using this patent, we will focus on the development of highly competitive products through efficient research activities such as the development of durable dermal filler products based on REJUVIEL, a hyaluronic acid dermal filler product.”
PharmaResearch is a regenerative medicine-based bio-pharmaceutical company that manufactures and sells medicines, medical devices, cosmetics, and health functional food, focusing on tissue regeneration materials DOT™ PDRN and DOT™ PN. The representative products are REJURAN, CONURAN, REJURAN Cosmetics, Re-AN Eye Drops, and Zadaxin.